ProCE Banner Activity

Lung Cancer: Looking Ahead to the 2016 Clinical Oncology Meeting

Conference Coverage
Clinical Thought
Here are the studies being presented at ASCO 2016 that David R. Gandara, MD, and I think are most likely to affect clinical practice in our patients with lung cancer.

Released: May 31, 2016

Expiration: May 30, 2017

No longer available for credit.

Share

Faculty

Heather Wakelee

Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals

Faculty Disclosure

Primary Author

Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Heather Wakelee, MD, has disclosed that she has received consulting fees from ACEA, Genentech, Helsinn, Peregrine, and Pfizer; and funds for research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Clovis, Exelixis, Genentech/Roche, Gilead, Lilly, Novartis, Pfizer, Pharmacyclics, and Xcovery.

Additional Information

Program Medium

This program has been made available online.